s6y

Maze Therapeutics, Inc.

Ticker
MAZE
CIK
1842295
Industry
Biological Products, (No Diagnostic Substances)

Financials 8

  1. 10-Q Quarterly Report for period ending Sep 30, 2026
  2. 10-Q Quarterly Report for period ending Jun 30, 2026
  3. 10-Q Quarterly Report for period ending Mar 31, 2026
  4. 10-K Annual Report for period ending Dec 31, 2025
  5. 10-Q Quarterly Report for period ending Sep 30, 2025
  6. 10-Q Quarterly Report for period ending Jun 30, 2025
  7. 10-Q Quarterly Report for period ending Mar 31, 2025
  8. 10-K Annual Report for period ending Dec 31, 2024

News 17

  1. 8-K Current report filing
  2. 8-K Current report filing
  3. 8-K Current report filing
  4. 8-K Current report filing
  5. 8-K Current report filing
  6. 8-K Current report filing
  7. 8-K Current report filing
  8. 8-K Current report filing
  9. 8-K Current report filing
  10. 8-K Current report filing

All 17 news filings

Ownership 108

  1. 4 Statement of changes in beneficial ownership of securities
  2. 4 Statement of changes in beneficial ownership of securities
  3. 4 Statement of changes in beneficial ownership of securities
  4. 4 Statement of changes in beneficial ownership of securities
  5. 4 Statement of changes in beneficial ownership of securities
  6. 4 Statement of changes in beneficial ownership of securities
  7. 4 Statement of changes in beneficial ownership of securities
  8. 4 Statement of changes in beneficial ownership of securities
  9. 4 Statement of changes in beneficial ownership of securities
  10. 4 Statement of changes in beneficial ownership of securities

All 108 ownership filings

Prospectus 19

  1. 424B5 Prospectus filed pursuant to Rule 424(b)(5)
  2. S-8 Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
  3. S-3ASR Automatic shelf registration statement of securities of well-known seasoned issuers
  4. 424B3 Prospectus filed pursuant to Rule 424(b)(3)
  5. S-1 General form of registration statement for all companies including face-amount certificate companies
  6. S-8 Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
  7. 424B4 Prospectus filed pursuant to Rule 424(b)(4)
  8. S-1MEF A new registration statement filed under Rule 462(b) to add securities to a prior related effective registration statement filed on Form S-1
  9. S-1/A General form of registration statement for all companies including face-amount certificate companies
  10. S-1/A General form of registration statement for all companies including face-amount certificate companies

All 19 prospectus filings

Proxies 2

  1. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
  2. DEF 14A Definitive proxy statements

Other 71

  1. SCHEDULE 13G/A
  2. 144 Filing for proposed sale of securities under Rule 144
  3. 144 Filing for proposed sale of securities under Rule 144
  4. 144 Filing for proposed sale of securities under Rule 144
  5. 144 Filing for proposed sale of securities under Rule 144
  6. 144 Filing for proposed sale of securities under Rule 144
  7. 144 Filing for proposed sale of securities under Rule 144
  8. 144 Filing for proposed sale of securities under Rule 144
  9. 144 Filing for proposed sale of securities under Rule 144
  10. 144 Filing for proposed sale of securities under Rule 144

All 71 other filings